EXICURE, INC. Increase (Decrease) in Other Receivables
EXICURE, INC. (XCUR) reported Increase (Decrease) in Other Receivables of -$50.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-14
- EXICURE, INC. increase (decrease) in other receivables for the quarter ending 2026-06-30 was -$52.00K.
- EXICURE, INC. increase (decrease) in other receivables for the quarter ending 2026-03-31 was $2.00K.
- EXICURE, INC. increase (decrease) in other receivables for the quarter ending 2025-09-30 was -$23.00K, a 102.91% decline year-over-year.
- EXICURE, INC. increase (decrease) in other receivables for the quarter ending 2025-06-30 was -$95.00K, a 117.46% decline year-over-year.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month |
|---|---|---|---|
| 2026-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$50.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-29 | ||
| 2025-09-30 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$118.00K derived: sum of 2 quarters · filed 2026-08-14 | -$1.46M 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.43M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$1.34M 10-Q · filed 2026-05-29 | ||
| 2024-09-30 | $791.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.33M derived: sum of 2 quarters · filed 2025-11-07 | $1.33M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $544.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $544.00K 10-Q · filed 2025-08-08 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-06-27 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |